Skip to main content
OpenTrials

Clinical trial condition

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Explore clinical trials studying High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements. Study availability and eligibility vary by location and protocol.

11 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trial results

Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

NCT07069699

Conditions
Burkitt Lymphoma, DNA Virus Infections, Double-Expressor Lymphoma, +16 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of Kansas Clinical Research Center Fairway, Kansas, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details
Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

NCT05600686

Conditions
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, +1 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UC San Diego Moores Cancer Center San Diego, California, United States
View Trial Details
Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

NCT05890352

Conditions
Grade 3b Follicular Lymphoma, Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma, +14 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
View all 104 locations
View Trial Details
Completed

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

NCT03742258

Conditions
Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +15 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Northwestern Lake Forest Hospital Lake Forest, Illinois, United States
View Trial Details
Active, Not Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

NCT04799275

Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, +30 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions
ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
View all 33 locations
View Trial Details

Related conditions